News

1 3 4 5 6 7 8 9 12 17 22
NEWS

SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline

  • PPF Group provides funding to advance SOTIO through key clinical milestones
  • Proceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial
  • Three programs (SOT102, BOXR1030, and SOT201) to advance through phase 1

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until end of 2023.

NEWS

SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences

  • SOTIO Biotech licenses LegoChem Biosciences (LCB) technology for five new antibody-drug conjugate (ADC) programs
  • Rights to LCB’s ADC platform acquired for total of up to $1027.5 million payable based on certain developments and regulatory achievements, including upfront and near-term success dependent milestones worth up to $29.5 million
  • SOTIO will be responsible for the research, development, manufacturing and commercialization of the ADC products

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc. (LCB, KOSDAQ: 141080), a biotechnology company focused on developing its clinical-stage platform technology enabling antibody-drug conjugates (ADCs) with an excellent therapeutic index. SOTIO will obtain rights to deploy LCB’s ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens.

NEWS

SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors

  • Majority of patients receiving SOT101 (SO-C101) + pembrolizumab had confirmed clinical benefit
  • Clinical responses have been observed in patients progressing on previous anti-PD-1 treatment
  • SOT101 monotherapy and in combination with pembrolizumab was well tolerated in patients with advanced/metastatic solid tumors

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced new data from the ongoing Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, as a monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors. The data are presented in three posters at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting from November 10-14, 2021.